Valued at a market cap of $28 billion, San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that ...

DexCom, Inc. DXCM is well-positioned for growth in the coming quarters, supported by the significant potential of the ...

With no single headline event driving DexCom (DXCM) recently, investors are watching the stock after a gain of about 21% over the past month and roughly 7% over the past 3 months. See our latest ...

DexCom (NASDAQ:DXCM) stock saw a notable increase of 16% on Friday following the announcement of its Q1 earnings and a share buyback program. The company’s first-quarter sales hit $1.04 billion, ...

DexCom posts steady profits and global reach, while Insulet surges ahead with rapid revenue growth and a focused product line ...

It's been a tough year for DexCom (NASDAQ: DXCM), whose stock price is down 25% since the start of 2025. It's a surprising performance, given that the overall stock market has been doing well; you ...

They have outpaced the S&P 500 over the past 10 years.

DexCom (NASDAQ:DXCM) stock experienced a significant 16% surge on Friday following its Q1 earnings release and a share buyback announcement. The company’s first-quarter sales reached $1.04 billion, ...

CHONGQING, CHINA - APRIL 26: In this photo illustration, the logo of Dexcom, Inc. is displayed on a smartphone screen, with the company's latest stock market chart visible in the background, ...

DexCom is a major player in the continuous glucose monitoring (CGM) market. These devices help diabetes patients monitor their blood sugar levels in real time throughout the day, an activity that is ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A strong fourth-quarter 2024 performance and a series of favorable coverage decisions are ...